Arrowhead Pharmaceuticals, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ARWR research report →
About the company
Arrowhead Pharmaceuticals, Inc. , founded in 1989 and based in Pasadena, California, is a biopharmaceutical company dedicated to discovering and advancing innovative treatments for complex and challenging-to-treat diseases within the United States. The company's extensive therapeutic pipeline primarily leverages RNA interference (RNAi) technology.
- CEO
- Christopher R. Anzalone
- IPO
- 1993
- Employees
- 609
- HQ
- Pasadena, CA, US
Price Chart
- Market Cap
- $11.83B
- P/E
- -39.75
- P/S
- 19.02
- P/B
- 19.48
- EV/EBITDA
- -96.79
- Div Yield
- 0.00%
- Gross Margin
- 100.00%
- Op Margin
- -35.67%
- Net Margin
- -48.38%
- ROE
- -55.45%
- ROIC
- -10.98%
- Revenue
- $829.45M · 23258.15%
- Net Income
- $-1,631,000 · 99.73%
- EPS
- $-0.01 · 99.76%
- Op Income
- $98.35M
- FCF YoY
- 125.96%
- 52W High
- $84.55
- 52W Low
- $14.30
- 50D MA
- $76.46
- 200D MA
- $60.46
- Beta
- 1.26
- Avg Volume
- 2.04M
Get TickerSpark's AI analysis on ARWR
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 15, 26 | Cohen Matthew Gregory | other | 11,882 |
| Jun 15, 26 | Cohen Matthew Gregory | other | 0 |
| May 12, 26 | Lu Hongbo | sell | 2,970 |
| Apr 22, 26 | Apel Daniel Joseph | sell | 3,208 |
| Apr 22, 26 | Apel Daniel Joseph | sell | 1,157 |
| Apr 22, 26 | Apel Daniel Joseph | sell | 8,730 |
| Apr 23, 26 | Hamilton James C | sell | 10,000 |
| Mar 5, 26 | Hamilton James C | sell | 10,000 |
| Jan 6, 26 | Hamilton James C | other | 75,000 |
| Jan 6, 26 | Apel Daniel Joseph | other | 75,000 |
Our ARWR coverage
Recent articles, reports, and earnings notes.
No research on ARWR yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ARWR report →Similar companies
Peers in the same neighborhood.